$375 Million is the total value of MPM BioImpact LLC's 32 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $69,216,825 | -15.9% | 7,648,268 | 0.0% | 18.48% | +11.5% | |
| RPTX | Repare Therapeutics, Inc. | $19,809,376 | +14.2% | 1,639,849 | 0.0% | 5.29% | +51.3% | |
| ITOS | iTeos Therapeutics, Inc. | $19,118,076 | -17.3% | 1,745,943 | 0.0% | 5.10% | +9.6% | |
| NTLA | Intellia Therapeutics, Inc. | $17,221,485 | -22.5% | 544,639 | 0.0% | 4.60% | +2.8% | |
| CRNX | Crinetics Pharmaceuticals Inc. | $14,247,036 | +65.0% | 479,053 | 0.0% | 3.80% | +118.8% | |
| VERV | Verve Therapeutics, Inc | $11,376,284 | -29.3% | 857,940 | 0.0% | 3.04% | -6.2% | |
| RGNX | REGENXBIO Inc. | $10,809,578 | -17.7% | 656,718 | 0.0% | 2.89% | +9.2% | |
| RVMD | Revolution Medicines, Inc. | $7,567,933 | +3.5% | 273,408 | 0.0% | 2.02% | +37.1% | |
| AXSM | Axsome Therapeutics, Inc. | $6,540,726 | -2.7% | 93,586 | 0.0% | 1.75% | +29.0% | |
| HOWL | Werewolf Therapeutics, Inc. | $5,110,344 | -29.8% | 2,388,011 | 0.0% | 1.36% | -7.0% | |
| TVTX | Travere Therapeutics Inc. | $4,942,443 | -41.8% | 552,846 | 0.0% | 1.32% | -22.9% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $3,974,811 | -15.7% | 5,095,912 | 0.0% | 1.06% | +11.8% | |
| VRDN | Viridian Therapeutics Inc | $3,916,655 | -35.5% | 255,323 | 0.0% | 1.05% | -14.5% | |
| INZY | Inozyme Pharma Inc. | $1,373,068 | -24.6% | 326,921 | 0.0% | 0.37% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.